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ABSTRACT
Introduction We established a promising sialendoscopic 
treatment for in vivo enhancement of salivation in salivary 
glands affected by Sjögren’s syndrome (SS). In this 
technique, the ducts of the salivary glands are irrigated 
with saline and steroids. This allows for dilatation of ductal 
strictures and removal of debris. Unfortunately, it is not 
possible to assess the delivery and penetration of saline 
or medications in the ductal system and parenchyma. 
To address this problem, we will conduct contrast- 
enhanced ultrasound sialendoscopy (CEUSS) using sulphur 
hexafluoride microbubbles. To the best of our knowledge, 
microbubbles have never been used for the treatment of 
salivary glands in SS. It is, therefore, imperative to test this 
application for its safety and feasibility.
Methods and analysis A single- arm phase I study 
will be performed in 10 SS patients. Under local 
anaesthesia, ultrasound (US) guided infusion of the 
parotid and submandibular glands with microbubbles 
will be performed. Continuous US imaging will be used to 
visualise the glands, including the location of strictures and 
occlusions. Main outcomes will be the evaluation of safety 
and technical feasibility of the experimental treatment. 
Secondary outcomes will consist of determinations of 
unstimulated whole mouth saliva flow, stimulated whole 
mouth saliva flow, stimulated parotid saliva flow, clinical 
oral dryness, reported pain, xerostomia, disease activity, 
salivary cytokine profiles and clinical SS symptoms. Finally, 
salivary gland topographical alterations will be evaluated 
by US.
Ethics and dissemination Ethical approval for this 
study was obtained from the Medical Ethics Committee 
of the Amsterdam University Medical Centre, Amsterdam, 
The Netherlands (NL68283.029.19). data will be 
presented at national and international conferences and 
published in a peer- reviewed journal. The study will be 
implemented and reported in line with the Standard 
Protocol Items: Recommendations for Interventional 
Trials’ statement.
Trial registration numbers The Netherlands Trial 
Register: NL7731, MREC Trial Register: NL68283.029.19; 
Pre- results.
INTRODUCTION
Sjögren’s syndrome (SS) is an autoimmune 
disorder causing chronic inflammation and 
irreversible damage of the exocrine glands. 
SS is characterised by mononuclear infiltrates 
and immunoglobulin G plasma cells in sali-
vary and lacrimal glands, which leads to irre-
versible destruction of glandular tissue.1 SS 
affects 0.3–1 of 1000 persons with a female to 
male ratio of 9:1.2 3 SS causes a gradual reduc-
tion in the quantity and quality of saliva.4 
Because of hyposalivation, patients with SS 
suffer from a sensation of oral dryness (xero-
stomia) and its related complaints (diffi-
culty in eating and swallowing, altered taste 
and speech problems). They are also prone 
to developing progressive dental decay and 
Strengths and limitations of this study
 ► This will be the first study to examine the safety and 
technical feasibility of microbubbles, combined with 
sialendoscopy, in salivary glands of patients with 
Sjögren’s syndrome.
 ► This is a ‘single- arm’ trial. The data will be used to 
inform a future’s large multi- centre randomised con-
trolled trial comparing different treatment options.
 ► The present study is a non- randomised phase I 
trial; therefore, the results cannot be confirmatory, 
but will be indicative of the benefits of contrast- 
enhanced ultrasound sialendoscopy.
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chronic inflammation of the oral mucosa.5 Additionally, 
patients suffer from painful episodes of sialadenitis due to 
partial or complete obstruction of the saliva- transporting 
ducts caused by intraductal scar formation and fibrinous 
plaques.6–8
In recent years, we have established a promising sialen-
doscopic treatment of salivary- gland- related complica-
tions in patients with SS. In this technique, the ducts of the 
salivary glands are irrigated with saline and steroids. This 
minimally invasive technique allows dilatation of ductal 
strictures and removal of ductal debris. We showed allevi-
ation of some of the oral symptoms of patients suffering 
from SS and partial restoration of glandular function (ie, 
saliva flow).9–11
Although sialendoscopy in patients with SS has shown 
promising results, there are several limitations in the 
current approach. It is not possible to enter and explore 
all ducts with the current sialendoscopes because of 
decreasing ductal diameters from the main duct to 
terminal glandular tissue. In addition, it is difficult to 
intraoperatively evaluate therapeutic efficacy (ie, removal 
of obstructions and restoration of flow) and to assess the 
delivery and deep penetration of medication in the ductal 
system and parenchyma.
To address these limitations of sialendoscopy and to 
improve our therapy, we will conduct contrast- enhanced 
ultrasound sialendoscopy (CEUSS) using commercially 
available sulphur hexafluoride microbubbles (SonoVue 
Bracco Imaging SpA, Milan, Italy). These microbubbles, 
consisting of 5–10 µm gas- filled particles, were initially 
used as contrast agents to demonstrate occlusions of fluid 
flow, but are currently also being used in the cardiology 
field to dissolve arterial occlusions.12–15 The proposed 
mechanism of action is that microbubbles can oscillate 
under the influence of ultrasound (US).
In our approach, the microbubbles will serve multiple 
purposes. (1) The micrometre size of the microbubbles 
facilitates penetration into virtually all ducts, thereby 
allowing non- invasive high- resolution US imaging of the 
glands and, in particular, ductal obstructions (where 
microbubbles will accumulate). (2) The effect of US- en-
hanced sialendoscopy can be imaged directly by re- in-
fusion of microbubbles to assess the ‘new’ distribution 
pattern. If ductal obstructions have not yet been suffi-
ciently resolved, treatment can be repeated in the same 
session. (3) The level of glandular inflammation may 
concomitantly be reduced.
The sialendoscopic treatment we use currently resolves 
some SS symptoms, and we have evidence that sialen-
doscopy significantly improve low saliva flow in patients 
with SS, thereby reducing their oral dryness burden.10 11 
Sialendoscopy is a minimally invasive technique, which 
is clinically accepted to treat obstructive salivary gland 
diseases. The current project has the added value over 
normal sialendoscopy in that it encompasses non- 
invasive intraoperative visualisation and diagnostic 
imaging without exposure of patients to radiation, and 
we hypothesise that the irrigation- induced local hydro-
static pressure dissolves ductal occlusions and enhances 
saliva flow.
Microbubbles are widely used for various applications, 
both as a contrast agent and as a treatment modality. 
They have been used for US- assisted contrast imaging 
in salivary glands16 17 but are not for US- assisted contrast 
imaging in salivary glands affected by SS. It is, therefore, 
imperative that this new application is first tested for its 
feasibility and safety in a cohort of patients with SS.
The aim of this study is to assess the safety and prac-
tical applicability of CEUSS in the salivary glands of 
patients with SS. Practical applicability will be defined 
as accomplishment of the experimental protocol during 
the procedure. To evaluate functional outcomes, we will 
meticulously monitor for serious adverse events (SAEs) 
and assess whether changes in saliva flow, oral dryness 
indices and subjective mouthfeel occur. This evaluation 
will be performed in a phase I, single- centre, single- arm, 
exploratory study. The study protocol will be implemented 
and reported in line with the Standard Protocol Items: 
Recommendations for Interventional Trials’ statement.18
METHODS AND ANALYSIS
Study setting
This single- centre trial will be performed at the Depart-
ments of Oral and Maxillofacial Surgery/Oral Pathology 
and Radiology and Nuclear Medicine, Amsterdam 
University Medical Centre, VU University Amsterdam, 
Amsterdam, the Netherlands.
Participants and eligibility criteria
Participants will be recruited from our existing database 
of patients with SS. To be eligible to participate in this 
study, a subject must meet all of the following criteria: 
diagnosed with primary SS in agreement with the 2016 
American College of Rheumatology–European League 
Against Rheumatism (EULAR)19; age: ≥18 years and ≤75 
years; a remaining unstimulated whole mouth saliva flow 
(UWSF) of ≥0.02 mL/min and a remaining stimulated 
whole mouth saliva flow (SWSF) of ≥0.10 mL/min.
Potential subjects who meet any of the following 
criteria will be excluded from participation in this study: 
we are unable to identify or enter the orifice of the sali-
vary duct(s), as determined during assessment, 6 weeks 
before intervention (table 1); acute sialadenitis; severe 
illness or physical conditions interfering with the inter-
vention; use of sialogogue medication (ie, pilocarpine 
or cevimeline); a history of head and neck cancer radio-
therapy; presence of MALT lymphoma in the major sali-
vary glands; suspected acute coronary syndrome; recent 
percutaneous coronary intervention; acute or chronic 
severe (New York Heart Association (NYHA) class III/IV) 
heart failure; right- to- left shunts; severe pulmonary hyper-
tension (pulmonary artery pressure >90 mm Hg); uncon-
trolled hypertension; adult respiratory distress syndrome 
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this study should not be used in combination with dobu-
tamine in patients with cardiovascular instability, where 
dobutamine is contraindicated.
Patients are asked to participate in the study by a maxil-
lofacial surgeon or dentist (ie, investigators) at their first 
consultation appointment. At this time, the investigators 
will explain the study and provide the volunteers with the 
participant information and the informed consent letter. 
At the next appointment, there is the opportunity to ask 
questions about the study and volunteers can indicate 
whether they want to participate. If the participant wants 
to participate, they will sign the informed consent form 
(online supplemental file 1). The investigators also will 
sign the informed consent form. The anticipated date of 
first enrolment is July 2020.
Intervention
CEUSS is a classic endoscopic technique combined with 
US imaging, specially designed for application in large 
salivary glands. In every patient, under local anaesthesia, 
a US- guided infusion of microbubbles (SonoVue, Bracco 
Imaging SpA, Milan, Italy) into the parotid and subman-
dibular glands will be performed followed by activation 
of the microbubbles by US. A mixture of 0.3 mL of a 
second- generation contrast agent (SonoVue, Bracco, 
Milan, Italy) consisting of stabilised microbubbles of 
sulphur hexafluoride and 9.5 mL (0.9% w/v NaCl) will 
be used as the irrigation solution. After the orifice of 
the salivary gland duct to be treated is located, 0.5–1.0 
mL of 4% (w/v) articaine with 1:100 000 epinephrine 
(Septanest, Septodont, Saint- Maru- des- Fosses, France) is 
injected submucosally near the papilla. Next, the endo-
scope is properly positioned in the salivary duct under 
echoscopic guidance. Sialendoscopy with continuous US 
imaging will be performed using 0.8 mm or 1.1 mm diam-
eter Erlangen sialendoscopes (Karl Storz GmbH & Co, 
Tuttlingen, Germany). Sialendoscopy is always started by 
flushing the salivary duct system and filling it with approx-
imately 2 mL of irrigation solution to unfold the ducts. 
During sialendoscopy, irrigation fluid will continuously 
drain in a retrograde manner from the duct system via 
the ostium into the oral cavity and it is removed from the 
oral cavity by suction. Therefore, the irrigation fluid has 
to be replenished regularly throughout the procedure. 
For this, a small volume of irrigation fluid will be applied 
whenever the ducts collapse. This strategy results in an 
average application rate of about 0.5 mL irrigation fluid 
per minute.20 Stronger and longer lasting bursts of irri-
gation may be necessary during endoscopy to flush out 
plaques and microsialoliths from the salivary duct system 
and open strictures. On the surgeon’s instruction, the 
assisting nurse will perform intermittent flushing by 
manual pressure on the 10 mL syringe. Finally, an intra-
ductal bolus injection of the remaining irrigation solution 
will be administered under direct vision into the salivary 
glands and maintained in the glands by temporarily (±10 
min) occluding the ductal orifices with a microvascular 
clamp. During the procedure, continuous US imaging 
will be performed using a local transdermal US device to 





assessment Post- intervention assessment
T-6 T-4 T0 T1 T2 T8 T16 (closeout)
Enrolment               
  Eligibility screen X             
  Informed consent   X           
Interventions               
  CEUSS     X         
Assessments               
  Safety       X X X X
  Technical feasibility and applicability     X         
  UWSF, SWSF and SPSF X X   X X X X
  Analysis of the salivary cytokine profiles   X   X X X X
  CODS   X   X X X X
  XI score   X   X X X X
  ESSPRI score   X   X X X X
  MPQ   X   X X X X
  Salivary gland topography   X   X     X
CEUSS, contrast- enhanced ultrasound sialendoscopy; CODS, Clinical Oral Dryness Score; ESSPRI, European League Against Rheumatism 
(EULAR) Sjögren’s Syndrome Patient Reported Index; MPQ, McGill Pain Questionnaire; SPSF, stimulated parotid saliva flow; SWSF, 
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visualise the glands, including the location of strictures 
and occlusions. This will be performed at a fixed US 
resonance frequency of 9 MHz, performed under low US 
mechanical index settings (eg, MI: 0.1), to avoid disrup-
tion and premature activation of the bubbles.17 It will be 
visualised how far and how quick the microbubbles enter 
the ductal system of the salivary glands and the effect of 
the sialendoscopic rinsing procedure on strictures (ie, 
occlusions or blockades) will be monitored.
Outcomes
Main outcomes will be an evaluation of the safety and 
practical applicability of the experimental treatment. 
Safety will be determined by unanticipated treatment- 
related mortality, and the occurrence of adverse events 
(AEs) and SAEs. AEs will be defined as any undesirable 
experience occurring to a subject during the experi-
mental treatment period, whether or not related to the 
investigational intervention. SAEs will be defined as any 
untoward medical occurrence or effect that, at any dose, is 
life threatening (at the time of the event); requires hospi-
talisation or prolongation of existing in- patients’ hospi-
talisation; results in persistent or significant disability or 
incapacity or is a new event of the trial likely to affect the 
safety of the subjects, such as an unexpected outcome of 
an adverse reaction. Practical applicability will be defined 
as accomplishment of the experimental protocol during 
the procedure.
Exploratory outcomes of CEUSS will include measure-
ments of UWSF, SWSF, stimulated parotid saliva flow and 
the Clinical Oral Dryness Score (CODS).21 22 Changes 
due to CEUSS in reported pain, mouthfeel and clinical 
SS symptoms will be determined in comparison to initial 
values using a set of validated questionnaires, that is, the 
McGill Pain Questionnaire (MPQ),23 Xerostomia Inven-
tory (XI)24 and EULAR Sjögren’s Syndrome Patient 
Reported Index (ESSPRI).25 26 Furthermore, changes in 
salivary cytokine profiles will be determined (interleukin 
(IL) 1β, IL-6, B- cell Activating Factor (BAFF), IL-12, 
IL-18 and Tumor Necrosis Factor α (TNFα)). Finally, 
salivary gland topographical alterations will be evaluated 
by US using the Hočevar Score.27 The echostructure of 
the treated glands will be graded at T-4 (4 weeks before 
intervention), T1 (1 week after intervention) and T16 (16 
weeks after intervention).
Participant timeline
The study encompasses an enrolment and assessment 
period of 6 weeks and a patient follow- up period of 16 
weeks. The schedule of enrolment, interventions and 
assessments is presented in table 1.
Sample size
Ten patients will be included. Usually, 10–20 patients are 
usually investigated in a phase I trial to confirm the occur-
rence of toxic effects or (S)AEs that are anticipated to be 
<20%.
Data collection methods
Saliva flow and analysis
Each patient will be instructed to refrain from drinking, 
eating, chewing, brushing teeth and smoking for 90 
min before each visit. To minimise diurnal variation, all 
appointments for each patient will be at the same time 
of day and in the same room (temperature: 21°C±2°C 
and humidity: 50%–60%). UWSF and SWSF samples will 
be collected every 30 s over 5- minute periods in sepa-
rate pre- weighed containers placed in crushed ice to 
prevent proteolysis. For the UWSF samples, each patient 
will be instructed to start collecting saliva immediately 
after an initial swallow and expectoration. For the SWSF 
samples, patients will be instructed to chew a 5×5 cm 
sheet of paraffin (ParafilmM, Pechiney, Chicago, Illinois, 
USA) and then expectorate. The patients are instructed 
to chew at a rate of 60 strokes/min, which is indicated 
by a metronome. This chewing rate reflects a normal 
chewing rate. Each container will be reweighed after 
saliva collection and the weight of the empty container 
will be subtracted to determine UWSF and SWSF rates 
(mL/min).28 Parotid- stimulated saliva will be collected 
from each parotid gland using plastic tubes and modified 
Lashley cups. Citric acid (2% w/v) will be applied to the 
lateral border of the tongue using a cotton wool swab at 
30- second intervals to stimulate parotid gland secretion.29 
The same observer will perform all assessments. See also 
the standard operating procedure in the supplemental 
materials (online supplemental file 2).
Saliva will be transferred to Eppendorf tubes (Eppen-
dorf AG, Hamburg, Germany) and centrifuged for 5 min 
at 10 000 g at 4°C30 to remove debris. After centrifuging, 
the saliva will be stored at –80°C in plastic containers 
(Cryogenic Vials Nalgene tubes, Nalgene Nunc, Roch-
ester, New York, USA). Every volunteer will be given a 
labelled code of 1–10, based on the order of application. 
Only principal investigators can access the coded data. 
All samples will be stored for analysis of salivary cytokine 
profiles (IL-1β, IL-6, BAFF, IL-12, IL-18 and TNF) by our 
collaborators (University of Florida and University of 
Missouri, USA).
XI score
The summated XI is an 11- item validated questionnaire 
about oral dryness and mouthfeel. A 5- point Likert scale 
is used to indicate symptom frequency. The values from 
the questions are summed to give a total XI score of 11 
(no dry mouth) to 55 (extremely dry mouth).24
European League Against Rheumatism (EULAR) Sjögren’s 
Syndrome Patient Reported Index (ESSPRI)
Disease symptoms (pain, fatigue and dryness) will 
be assessed using the 10- point scale ESSPRI patient- 
administered questionnaire. The ESSPRI has high 
sensitivity for detection of changes in symptoms after a 
therapeutic intervention is performed. Only the dryness 
subscale will be included in the analysis. A change of 2 or 
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Clinical Oral Dryness Score (CODS)
The CODS is a validated clinical guide designed to 
assess oral dryness using clinical and visual inspection of 
the oral cavity. It includes clinical signs of oral dryness, 
such as the presence of frothy saliva and stickiness of the 
dental mirror to the tongue and buccal fold. The values 
for each of 10 characteristics will be summed to result in 
a score ranging from 0 (no oral dryness) to 10 (extreme 
oral dryness).21 22
Pain score
The Dutch version of the MPQ is a three- part pain 
assessment tool that measures several dimensions of 
the patient’s pain experience. The first part consists of 
an anatomic drawing of the human form on which the 
patient marks where his or her pain is located. The 
second part of the MPQ is a verbal descriptive scale that 
allows the patient to record the intensity level of his or 
her current pain experience. The third part of the MPQ 
is a pain verbal descriptor inventory consisting of 72 
descriptive adjectives. The patient is asked to review this 
list of pain descriptors and circle the ones that serve to 
best describe his or her current pain experience. Each 
part or dimension of the MPQ is individually scored and 
a cumulative total score is also recorded.23
Evaluation of the major salivary glands by US
The Hočevar scoring system will be used to investigate: 
(1) parenchymal echogenicity compared with the thyroid 
gland, graded 0–1; (2) homogeneity, graded 0–3; (3) the 
presence of hypoechogenic areas, graded 0–3; (4) hyper-
echogenic reflections, graded 0–3 in parotid glands and 
0–1 in submandibular glands and (5) clearness of the 
salivary gland border, graded 0–3, in both parotid and 
submandibular salivary glands. Total US score is the sum 
of these five domains and can range from 0 to 48.27
Data management and confidentiality
A data management plan, according to the findable, 
accessible, interoperable and reusable principles, will use 
Amsterdam University Medical Centre (UMC) Clinical 
Research Bureau (CRB) guidelines. We will make use of 
restricted access to the data. We will keep an electronic log 
of patients who fulfil the eligibility criteria, patients who 
are invited to participate in the study, patients recruited 
and patients who withdraw from the study. Reasons for 
non- recruitment will also be recorded. During the course 
of the study, we will document reasons for withdrawal 
and failure to follow- up. The data will be stored electron-
ically in case report forms (CRFs) software with audit 
trail functionality and will be audited by the Institutional 
CRB. The Good Clinical Practice (GCP)/Good Manufac-
turing Practice (GMP) approved electronic CRF software 
will be from Castor EDC (Castor EDC, Amsterdam, the 
Netherlands).
Every volunteer will be marked with a number 1–10 
(based on the order of application) for de- identification 
purposes. Only de- identified information will be stored 
and participants will only be identifiable by their unique 
study numbers, which will be kept in a separate file. The 
data will be securely stored on these servers for 15 years 
according to national guidelines. The principal investi-
gator will have access to the final trial data set.
Statistical methods
A descriptive analysis of the primary outcome measures 
(AEs and SAEs) will be performed. Wilcoxon signed- rank 
tests (data without a normal distribution) or linear mixed 
models (data with a normal distribution) will be used 
to examine differences between subsequent timepoints 
for the secondary outcome measures. Furthermore, esti-
mates of the means and SD of the parameters listed in 
previous paragraphs will be used for determination of the 
sample size for a subsequent randomised controlled trial.
Data monitoring and auditing
An independent quality- monitoring official will monitor 
the data by the GCP guidelines. The informed consent 
forms of a selection of participants will be checked. During 
the onsite monitoring, Source Data Verification will be 
performed (a check if the data in the CRFs (research 
forms/questionnaires) matches the source data (patient 
records, laboratory results, etc). The intensity of this veri-
fication is related to the risks of the study. Inclusion and 
exclusion criteria and the primary outcome measure of 
the study will always be checked based on a monitoring 
plan designed by VU Medical Centre’s CRB. The monitor 
will also check if (S)AEs are reported properly within the 
time limits, as set by legislation and regulation. During 
the study, the independent monitor schedules four moni-
toring visits. The first visit is scheduled after the inclusion 
of the third participant, the second visit is scheduled 6 
months later, the third visit is 1 year after the second visit 
and finally a closeout visit.
Harms
A reported side effect of sialendoscopy is postoperative 
swelling. Postoperative swelling usually occurs during the 
initial 48 hours and may last for 3–5 days after the proce-
dure. A possible but rare complication is perforation of 
the salivary duct and the creation of tissue damage due 
to the application of excessive force. When this occurs 
during the procedure, the treatment will be terminated 
immediately. Spontaneous wound healing is expected 
within 1 week, usually apparent within 1–2 days. The 
patient will be recalled to the clinic 1 week after this AE 
for a follow- up. In a previous study, we showed that classic 
sialendoscopy is a safe method to use in patients with SS 
with a low number of complications.9
US is a safe and non- invasive imaging technique. 
According to the European Medicines Agency (EMA) 
guidelines, the most common side effects of SonoVue 
microbubbles injected into a vein are headache, nausea 
(feeling sick) and reactions at the injection site, which 
are seen in up to 1 in 100 patients. In the literature, a 
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hexafluoride microbubbles as an US contrast agent for 
clinical applications in abdominal and superficial organs 
has been reported.31 The SonoVue microbubble has 
been approved in Europe and other countries for the 
improvement of endocardial border delineation during 
echocardiography and other non- cardiac applications.32 
Throughout Europe, a number of serious allergic reac-
tions with probable secondary cardiovascular problems 
have been reported to national and international registry 
authorities.32 33 Three of these reports included a fatal 
outcome soon after the administration of SonoVue in 
patients with severe coronary artery disease. Despite 
questions about the causal relationship, the EMA took 
precautionary measures to limit the use of SonoVue in 
patients with cardiac disease ( www. emea. eu. int/ human-
docs/ Humans/ EPAR/ SonoVue/ SonoVue. htm). As a 
result of the EMA intervention, SonoVue is contraindi-
cated in cardiac patients with suspected acute coronary 
syndrome, recent percutaneous coronary intervention, 
acute or chronic severe (NYHA class III/IV) heart failure 
or severe cardiac dysrhythmias. In a study investigating 
30 222 patients undergoing US- enhanced sonography 
of abdominal and superficial organs, no patient died as 
a result of any adverse reaction.31 Six patients (0.020%) 
had adverse reactions of varying degrees, including two 
patients (0.007%) who had signs of early anaphylactic 
shock (chest tightness, palpitations, sweating, a rapid and 
weak pulse followed by cyanosis, a disappearing pulse 
and a drop in blood pressure) that improved after active 
resuscitation. The remaining four patients developed 
the following: redness and a rash on the arm above the 
injection site, nasal bleeding with nausea, nausea with 
vomiting and back pain with numbness of the lips and 
limbs. Symptoms in these four patients self- resolved after 
a period of rest. In 2009, another group reviewed all 
adverse effects in 352 consecutive cases treated in their 
echocardiographic laboratory.34 During a 4- year period, 
352 SonoVue contrast echocardiography studies were 
performed in 274 patients for a variety of reasons. One 
hundred and ninety- eight patients underwent only one 
SonoVue study, whereas 77 patients underwent multiple 
SonoVue studies. Mild adverse reactions, including skin 
erythema and mild sinus tachycardia, were seen in four 
patients (1.1%). Three patients were referred for left 
ventricular (LV) function assessment and one for exclu-
sion of an LV thrombus. These mild reactions were 
present in 2 out of the 198 patients (1.0%) who received 
SonoVue only once, and two out of the 76 patients 
(2.6%) who received SonoVue twice. All four patients 
were successfully treated with intravenous clemastine 
and hydrocortisone. During the same 4- year period, an 
additional three patients (0.9%), who received SonoVue 
echocardiography for the first time, experienced a severe 
anaphylactic reaction.
It should be emphasised that in our study, the micro-
bubbles will not be injected intravenously but into the 
ducts of salivary glands. Therefore, the microbubbles 
will not enter the bloodstream and we presume that the 
occurrence of adverse reactions, as described below, will 
be more limited compared with intravenous infection. 
Nevertheless, an emergency plan and rescue measures for 
adverse reactions will be established by cooperating with 
the cardiology and emergency departments. Intravenous 
anti- allergic and anaphylactic drugs (H1 and H2 antihis-
tamines, corticosteroids and epinephrine) will be avail-
able in the echocardiography/sialendoscopy room in 
addition to standard resuscitation equipment.35 Patients 
also will be monitored for at least 30 min after the use 
of microbubbles. The AEs and SAEs will be monitored 
continuously and recorded. All AEs will be followed until 
they have abated, or until a stable situation has been 
reached. Depending on the event, follow- up may require 
additional tests or medical procedures as indicated, and/
or referral to either a general physician or a medical 
specialist.
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason, 
if they wish to do so, without consequences. The investi-
gator can decide to withdraw a subject from the study for 
urgent medical reasons. Participants may withdraw from 
the study at any time for any reason if they wish to do so 
without any consequences. The investigator can decide 
to withdraw a subject from the study for urgent medical 
reasons. A patient will be withdrawn during the interven-
tion in the rare event of perforation of the salivary duct 
with the creation of a passage or if it is not possible to 
enter the salivary duct. Patients that withdraw from the 
study will be replaced until T2, so that data will still be 
available from at least 10 participants. The study will be 
terminated prematurely, if more than 50% of the patients 
withdraw at T2 or if no more than 5 patients are willing to 
participate during the first year.
Compensation for harm
The investigator has insurance, which is in accordance 
with the legal requirements in the Netherlands (Article 7 
Wet Medisch- wetenschappelijk Onderzoek met mensen/
Medical Research Involving Human Subjects Act 
(WMO)). This insurance provides coverage for damage 
to research subjects through injury or death caused by 
the study. The insurance applies to damage that becomes 
apparent during the study or within 4 years after the end 
of the study.
ETHICS AND DISSEMINATION
The Medical Research Ethics Committee (MREC) 
of the Amsterdam UMC/VU Medical Centre (ID: 
NL68283.029.19) approved the study protocol and the 
study is being conducted in accordance with the Decla-
ration of Helsinki. Any protocol amendments during 
the study will be submitted to the MREC and changed 
accordingly in the relevant registries. A written informed 
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The results of this study will be submitted for publica-
tion in a peer- reviewed journal, regardless of the outcome 
of this study, in accordance with personal data privacy and 
other applicable legislations and the Central Committee 
on Research Involving Human Subjects (Centrale 
Commissie Mensgebonden Onderzoek (CCMO)) 
statement on publication policy. The data will also be 
presented at national and international conferences. All 
collected data will be deposited in an open access digital 
repository in an anonymous form.
Patient and public involvement
A patient advisory group from the Nederlandse Vereni-
ging voor Sjögren Patiënten/Dutch Society partnered 
with us for the design of the study, the informational 
material to support the intervention and review the 
burden of the intervention from the patient’s perspec-
tive. This patient advisory group will meet on a regular 
basis for the duration of the study. At the end of the study, 
the patient advisory group will comment on the findings 
and will contribute to the dissemination plan.
DISCUSSION
To the best of our knowledge, this is the first study in 
which sialendoscopy and the use of US in combination 
with microbubbles in the salivary glands of SS patients 
will be investigated. Therefore, the aim of this study is to 
investigate the safety and practical applicability of CEUSS 
in salivary glands affected by SS.
US is an easily available, cost- effective and safe tech-
nique, without hazards from ionising radiation, which 
allows dynamic studies with real- time imaging during 
diagnostic or surgical procedures. Recently developed 
innovative techniques in US, such as CEUSS, have demon-
strated to be more accurate in US assessment. However, 
US is limited in its ability to visualise the salivary ducts.16 17 
The use of an intraductal contrast medium during US 
can enhance visualisation of the ductal system and paren-
chyma.17 36
In our study, the therapeutic efficacy and the delivery 
and deep penetration of saline and oscillating microbub-
bles in the ductal system and parenchyma after sialen-
doscopy will be evaluated using CEUSS. This approach 
allows high- resolution visualisation of both the ductal 
system and parenchyma without exposure to radiation, 
since microbubbles are used as a contrast medium.17 36 
If ductal obstructions are still present after re- infusion of 
microbubbles, sialendoscopy can be repeated in the same 
session.
Microbubbles have initially been used as diagnostic US 
contrast enhancers. However, the application of micro-
bubbles in research and off- label use is growing. Currently, 
microbubbles are also used as drug/gene delivery vehi-
cles, as O2 gas carriers, for delivery of drugs across the 
blood–brain barrier and for therapeutic thrombolytic 
purposes.37 38 In our current and subsequent studies, the 
therapeutic possibilities for removal of ductal obstructions 
will be further investigated. If successful, we plan in subse-
quent studies to combine microbubbles with therapeutic 
agents, and aim to enhance drug delivery to the salivary 
glands and improve outcomes in patients with SS.
Although the treatment described in the current study 
(ie, dissolution of strictures and occlusions of the glandular 
ducts using sialendoscopy) is technically a symptomatic 
solution, we have provided evidence that sialendoscopy 
is able to increase saliva flow significantly,9–11 reducing 
the burden of the patient with SS and increasing his/her 
quality of life considerably. The current project has the 
added value over normal sialendoscopy that it encom-
passes non- invasive intraoperative visualisation and diag-
nostic imaging without radiation exposure of the patient, 
and we hypothesise that this real- time evaluation of the 
dissolution of ductal occlusions may enhance the success 
of our sialendoscopic treatment. Also, solutions for severe 
dry mouth are currently an unmet need, which could be 
addressed by CEUSS in a large cohort of patient with SS 
worldwide.
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